A Toronto-based life sciences venture capital firm with offices throughout USA and Canada manages over $250M and is currently investing from a new fund closed in 2017. The firm typically makes initial investments ranging from $2-$6 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm expects to make 4-6 investments over the next 12 months.
The firm invests primarily in Therapeutics and Medical Devices, with selective investments in diagnostic imaging and Healthcare IT. The firm is looking for companies phase I and later that have at least some human proof-of-concept with either early human efficacy signs or very strong animal data coupled with human safety data.
The firm invests in companies throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply